FAQ

efaproxiral

Known as: 2-(4-(((3,5-dimethylanilino)carbonyl)methyl)phenoxy)-2-methylpropionic acid, 2-Dacmpp, Efaproxyn 
A synthetic small molecule with radiosensitizing activity. Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2014
051020022014

Related topics

Related topics

5 relations

Broader (4)

Aniline CompoundsAntisickling AgentsPropionatesRadiation-Sensitizing Agents

Narrower (1)

RSR 13

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
efaproxiral
Propionates
Radiation-Sensitizing Agents
Aniline Compounds
Antisickling Agents
RSR 13

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Trimethylaluminium mediated amide bond formation in a continuous flow microreactor as key to the synthesis of rimonabant and efaproxiral.
A safe, functional-group-tolerant and high-throughput version of the trimethylaluminium mediated amide bond formation reaction… (More)
Is this relevant?
2007
2007
Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases.
OBJECTIVE To determine whether efaproxiral, an allosteric modifier of hemoglobin, improves quality of life and quality of… (More)
Is this relevant?
2007
2007
The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice.
Efaproxiral, an allosteric modifier of hemoglobin, reduces hemoglobin-oxygen binding affinity, facilitating oxygen release from… (More)
Is this relevant?
2006
2006
Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.
PURPOSE To determine whether efaproxiral, an allosteric modifier of hemoglobin, improves survival in patients with brain… (More)
Is this relevant?
2006
2006
Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survival.
PURPOSE To determine the prognostic factors for radiographic response and its prognostic value for subsequent survival in… (More)
Is this relevant?
2006
2006
Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases
Efaproxiral (Efaproxyn™, RSR13), a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2) binding affinity… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Review
2006
Review
2006
Role of efaproxiral in metastatic brain tumors.
Brain metastases from breast cancer are common and cause significant morbidity and mortality. Treatment with whole-brain… (More)
Is this relevant?
2005
2005
Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
PURPOSE Efaproxiral (RSR13) reduces hemoglobin oxygen-binding affinity, facilitates oxygen release, and increases tissue pO2. We… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2005
2005
Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study.
PURPOSE To determine quantitatively the changes in oxygenation of intracranial tumors induced by efaproxiral, an allosteric… (More)
Is this relevant?
2004
2004
Efaproxiral: a novel radiation sensitiser.
Efaproxiral (RSR13) is a synthetic allosteric modifier of haemoglobin that reduces its oxygen binding affinity. By facilitating… (More)
Is this relevant?